Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Type of ANCA may be Superior to Clinical Phenotype in Distinguishing Different Clinical Entities in ANCA-associated Vasculitis

Version 1 : Received: 13 August 2022 / Approved: 17 August 2022 / Online: 17 August 2022 (09:58:51 CEST)

A peer-reviewed article of this Preprint also exists.

Konstantouli, A.M.; Lioulios, G.; Stai, S.; Moysidou, E.; Fylaktou, A.; Papagianni, A.; Stangou, M. Type of ANCA May Be Indispensable in Distinguishing Subphenotypes of Different Clinical Entities in ANCA-Associated Vasculitis. Life 2022, 12, 1467. Konstantouli, A.M.; Lioulios, G.; Stai, S.; Moysidou, E.; Fylaktou, A.; Papagianni, A.; Stangou, M. Type of ANCA May Be Indispensable in Distinguishing Subphenotypes of Different Clinical Entities in ANCA-Associated Vasculitis. Life 2022, 12, 1467.

Journal reference: Life 2022, 12, 1467
DOI: 10.3390/life12101467

Abstract

The traditional nomenclature system for classifying Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV), based on clinical phenotype, described Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Microscopic Polyangiitis (MPA) as distinct clinical entities. This classification has proved its expedience in clinical trials and every day clinical practice, yet, a substantial overlap in clinical presentation still exists, and often causes difficulties in prompt definition and clinical distinction. Additionally, new insights into the AAV pathogenesis point out that PR3 and MPO-AAV may not represent expressions of the same disease spectrum but rather two distinct disorders, as they display significant differences. Thus, it is supported that a classification based on ANCA serotype (PR3-ANCA, MPO-ANCA or ANCA-negative), could be more accurate and also closer to the nature of the disease, instead of the phenotype-based one. This review aims to elucidate the major differences between PR3 and MPO-AAV, in terms of epidemiology, pathogenesis, histological and clinical manifestations, and response to therapeutic approaches.

Keywords

ANCA-associated vasculitis; Proteinase 3; Myeloperoxidase; Clinical Phenotype; Outcome

Subject

MEDICINE & PHARMACOLOGY, General Medical Research

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.